Learn more about Neovii world
The epitope-based vaccine will target the most vulnerable part of the viral spike protein. Rapperswil, Switzerland and Tel Aviv, Israel, 12th May 2020 – Ramot, Tel Aviv University’s technology transfer company, and Neovii, a Swiss-based biopharmaceutical company and a member of Israel-based Neopharm Group, announced today that they have signed a research and license agreement to develop a novel and potentially […]
Neovii & Mundipharma Confirm In-licensing Agreement for the Development and Promotion of Grafalon® in China and Japan for Solid Organ & Stem Cell Transplant Neovii and Mundipharma have entered into an agreement giving Mundipharma the rights to develop and distribute its polyclonal antibody immunosuppressant Grafalon®, in China and Japan from end October 2018. Grafalon® is currently approved for prevention of […]
Rapperswil, Switzerland, September 15, 2017 – Alexandre Sudarskis, Chief Executive Officer (CEO) of Neovii Pharmaceuticals will step down as CEO having reached retirement age. Neovii Pharmaceuticals appointed Juergen Pohle, Chief Commercial Officer, as CEO and Managing Director of Neovii as of January 1, 2018. CEO since June 2014, Alexandre Sudarskis established Neovii Pharmaceuticals’ headquarters in Switzerland […]
